Clinical trials: Leukemia, B-Cell, Chronic
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
This phase I trial tests the safety and side effects of zanubrutinib in combination with odronextamab and how well it works in treating patients with Richter's transformation.
- Conditions
- Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06735664
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- City of Hope Medical Center
B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage I Chronic Lymphocytic Leukemia
- Trial name
- NCT00377104
- Testing
- alvocidib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
This phase II trial studies how well the DIScussion of COst (DISCO) application (app) works in improving financial outcomes in patients with hematologic cancer.
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Plasma Cell Myeloma
- Trial name
- NCT04282343
- Testing
- The DISCO App, Usual Care
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's…
- Conditions
- B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT01351935
- Testing
- AVL-292
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Background: B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a patient's own cells (T lymphocytes) and grow them in the…
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia
- Trial name
- NCT03448393
- Testing
- CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to…
- Trial name
- NCT00003248
- Testing
- rituximab, fludarabine phosphate
- Where
- 34 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lymphoma
Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00014326
- Testing
- radiation therapy
- Where
- 15 sites in Belgium, Croatia and 4 more
- Volunteers
- 204 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with B cell lymphomas or leukemias that involves taking white blood cells from the patient, growing them…
- Conditions
- Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell
- Trial name
- NCT00924326
- Testing
- Fludarabine, Cyclophosphamide, Anti-cluster of differentiation 19 (CD19)-CAR PBL
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL)
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia.
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07205315
- Testing
- GT801 Injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Grit Biotechnology
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
- Trial name
- NCT03595917
- Testing
- ABL001, Dasatinib, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Marlise Luskin, MD
Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase I trial to study the effectiveness of combining MS-275 with isotretinoin in treating patients who have metastatic or advanced solid tumors or lymphomas.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT00098891
- Testing
- entinostat, isotretinoin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003335
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Lymphocytic Leukemia
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG induction therapy in participants with previously untreated CLL. The anticipated time on study treatment is 24 weeks.
- Trial name
- NCT02320487
- Testing
- Bendamustine, Obinutuzumab
- Where
- 26 sites in United States
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Follicular Lymphoma, Small Lymphocytic Lymphoma
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
- Trial name
- ILyAD (NCT03078855)
- Testing
- Vitamin D, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 211 people
- Sponsor
- Jonathan Friedberg
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect.
- Trial name
- NCT01181258
- Testing
- Rituximab, Interleukin-2, Natural killer cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
This phase II trial is studying how well AZD2171 works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
- Trial name
- NCT00321724
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.